---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116864"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:24:21.772588+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova

## Summary
- Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).
- Received CTA approval in Moldova for PBGENE-HBV, a first-in-human in vivo gene editing study for chronic hepatitis B.
- PBGENE-HBV targets and eliminates cccDNA and inactivates integrated HBV DNA, aiming for functional cure.
- Company to host investor event on Nov 15, 2024 prior to AASLD meeting to share preclinical safety package and Phase 1 trial details.
- Additional global CTA and IND submissions underway to accelerate patient enrollment across multiple sites.

## SEC filing metadata
- accession: 0000950170-24-116864
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/0000950170-24-116864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/dtil-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116864
- JSON: https://secwatch.observer/filing/0000950170-24-116864.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.